ARTICLE | Company News

BioDelivery, TTY BioPharm sales and marketing update

October 18, 2010 7:00 AM UTC

BioDelivery granted TTY exclusive rights to develop and commercialize BEMA Fentanyl in Taiwan. TTY is responsible for submitting a regulatory application in the territory. The adhesive disc formulation of fentanyl is approved in the U.S. and Canada as Onsolis to treat breakthrough pain in opioid-tolerant adult patients with cancer. BioDelivery will receive $300,000 up front and is eligible for up to $1 million in milestones, plus royalties. ...